GSK plc (LON:GSK) Insider Buys £7,198.44 in Stock

GSK plc (LON:GSKGet Free Report) insider Wendy Becker purchased 446 shares of the stock in a transaction dated Thursday, June 20th. The shares were bought at an average cost of GBX 1,614 ($20.51) per share, for a total transaction of £7,198.44 ($9,146.68).

GSK Price Performance

GSK stock opened at GBX 1,599 ($20.32) on Monday. GSK plc has a 12-month low of GBX 1,302.60 ($16.55) and a 12-month high of GBX 1,823.50 ($23.17). The stock has a market capitalization of £65.24 billion, a P/E ratio of 1,466.97, a P/E/G ratio of 1.19 and a beta of 0.27. The firm’s 50-day moving average is GBX 1,689.20 and its two-hundred day moving average is GBX 1,627.79. The company has a debt-to-equity ratio of 134.34, a current ratio of 0.87 and a quick ratio of 0.73.

GSK Cuts Dividend

The company also recently declared a dividend, which will be paid on Thursday, July 11th. Shareholders of record on Thursday, May 16th will be paid a dividend of GBX 15 ($0.19) per share. The ex-dividend date is Thursday, May 16th. This represents a dividend yield of 0.9%. GSK’s dividend payout ratio is currently 5,504.59%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on GSK. Barclays reaffirmed an “equal weight” rating and set a GBX 1,725 ($21.92) price target on shares of GSK in a research note on Tuesday, May 7th. Shore Capital reissued a “buy” rating on shares of GSK in a research note on Wednesday, June 12th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Tuesday, June 18th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 ($24.78) price objective on shares of GSK in a research note on Tuesday, June 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of GBX 1,675.63 ($21.29).

View Our Latest Stock Analysis on GSK

About GSK

(Get Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Recommended Stories

Insider Buying and Selling by Quarter for GSK (LON:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.